Markets
Vaxcyte Surges Pre-Market After Its 31-Valent Pneumococcal Vaccine Meets Every Phase 3 Endpoint
VAX-31 matched or beat Prevnar 20 and Capvaxive across shared serotypes in the 4,047-person OPUS-1 trial, but a licensing application is not planned until the first half of 2028.
By Marcus Elrod
Oct 5, 2026 · 2 min read
Vaxcyte said at 6 a.m. Eastern on Monday that VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, met all prespecified primary endpoints in OPUS-1, the pivotal Phase 3 trial in adults. Shares rose sharply in pre-market trading; Investing.com reported a gain of about 50%, a pre-market figure that will need confirming against the regular session.
Discussion (0)
Sign in to join the discussion.
Loading comments…
Marcus Elrod
Marcus tracks positioning, flows and rates. He writes CI's weekly market internals column.
Marcus Elrod writes for Corporate Insider Inc.